Design Therapeutics Drops Ahead of Jefferies, Trial Remains in Focus for DSGN
Design Therapeutics shares slid on Tuesday afternoon, dropping 24 cents to $10.20 in a broader biotech selloff. The Carlsbad, California-based firm was off roughly 2.3%. The SPDR S&P Biotech ETF lost about 4.0%, and the iShares Nasdaq Biotechnology ETF slipped about 3.0%. Design shares are in focus again since there’s been no new trial data update. The most recent post on Design’s investor page is still the May 28 Jefferies conference notice. Management is slated for a fireside chat in New York on June 4 at 1:25 p.m. EDT.